Coffee may reduce developing of Alzheimer's, Parkinson's

Image
ANI Washington D.C. [USA]
Last Updated : Nov 06 2018 | 12:00 PM IST

Love your coffee? Turns out, there could be more to that morning jolt of goodness than a boost in energy and attention. Drinking coffee may protect you against developing both Alzheimer's and Parkinson's disease.

According to a new study, approximately 500 billion cups of coffee are consumed worldwide each year. The findings of the study are published in the Journal of Frontiers in Neuroscience

"Coffee consumption does seem to have some correlation to a decreased risk of developing Alzheimer's disease and Parkinson's disease," said Dr. Donald Weaver, a researcher. "But we wanted to investigate why that is -- which compounds are involved and how they may impact age-related cognitive decline."

The team of researchers chose to investigate three different types of coffee - light roast, dark roast, and decaffeinated dark roast.

"The caffeinated and de-caffeinated dark roast both had identical potencies in our initial experimental tests," said Ross Dr. Mancini, a researcher. "So we observed early on that its protective effect could not be due to caffeine."

Dr. Mancini then identified a group of compounds known as phenylindanes, which emerge as a result of the roasting process for coffee beans. Phenylindanes are unique in that they are the only compound investigated in the study that prevents - or rather, inhibit - both beta-amyloid and tau, two protein fragments common in Alzheimer's and Parkinson's, from clumping. "So phenylindanes are a dual inhibitor. Very interesting, we were not expecting that," said Dr. Weaver.

As roasting leads to higher quantities of phenylindanes, dark roasted coffee appears to be more protective than light roasted coffee.

"It's the first time anybody's investigated how phenylindanes interact with the proteins that are responsible for Alzheimer's and Parkinson's," said Dr. Mancini. "The next step would be to investigate how beneficial these compounds are, and whether they have the ability to enter the bloodstream, or cross the blood-brain barrier.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 06 2018 | 11:54 AM IST

Next Story